NCT03515551View on ClinicalTrials.gov

Safety and Efficacy of IMCnyeso in Advanced NY-ESO-1 and/or LAGE-1A Positive Cancers

PHASE1/PHASE2TerminatedINTERVENTIONAL
Enrollment

29

Participants

Timeline

Start Date

June 15, 2018

Primary Completion Date

May 10, 2021

Study Completion Date

May 10, 2021

Conditions
Select Advanced Solid Tumors
Interventions
DRUG

IMCnyeso

Weekly IV infusions of IMCnyeso

Trial Locations (12)

10065

Memorial Sloan Kettering Cancer Center, New York

15232

UPMC - Hillman Cancer Center, Pittsburgh

19107

Thomas Jefferson University Hospital, Philadelphia

37203

Tennessee Oncology NASH - SCRI, Nashville

52242

University of Iowa Hospital and Clinics, Iowa City

63110

Washington University School of Medicine in St. Louis, St Louis

77030

MD Anderson Cancer Center, Houston

80045

University of Colorado Hospital, Aurora

M5G 2M9

Princess Margaret Cancer Centre, Toronto

W1G 6AD

Sarah Cannon Research Institute UK, London

M20 4BX

The Christie Hospital, Manchester

SW3 6JJ

Royal Marsden Hospital, Sutton

Sponsors

Lead Sponsor

Immunocore Ltd
All Listed Sponsors
lead

Immunocore Ltd

INDUSTRY

NCT03515551 - Safety and Efficacy of IMCnyeso in Advanced NY-ESO-1 and/or LAGE-1A Positive Cancers | Biotech Hunter | Biotech Hunter